BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 519879)

  • 1. Glucagon metabolism in normal subjects and in cirrhotic patients before and after portasystemic venous shunt surgery.
    Alford FP; Dudley FJ; Chisholm DJ; Findlay DM
    Clin Endocrinol (Oxf); 1979 Oct; 11(4):413-24. PubMed ID: 519879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of portasystemic venous shunt surgery on hyperglucagonaemia in cirrhosis: paired studies of pre- and post-shunted subjects.
    Dudley FJ; Alford FP; Chisholm DJ; Findlay DM
    Gut; 1979 Oct; 20(10):817-24. PubMed ID: 533693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbohydrate and lipid metabolism in cirrhosis. Evidence that hepatic uptake of gluconeogenic precursors and of free fatty acids depends on effective hepatic flow.
    Nosadini R; Avogaro A; Mollo F; Marescotti C; Tiengo A; Duner E; Merkel C; Gatta A; Zuin R; de Kreutzenberg S
    J Clin Endocrinol Metab; 1984 Jun; 58(6):1125-32. PubMed ID: 6373811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon.
    Sherwin RS; Fisher M; Bessoff J; Snyder N; Hendler R; Conn HO; Felig P
    Gastroenterology; 1978 Jun; 74(6):1224-8. PubMed ID: 648812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperglucagonaemia in cirrhosis. Relationship to hepatocellular damage.
    Smith-Laing G; Orskov H; Gore MB; Sherlock S
    Diabetologia; 1980 Aug; 19(2):103-8. PubMed ID: 7418964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperglucagonemia in liver cirrhosis with portal-systemic venous anastomoses: responses of plasma glucagon and gastric inhibitory polypeptide to oral or intravenous glucose in cirrhotics with normal or elevated fasting plasma glucose levels.
    McDonald TJ; Dupre J; Caussignac Y; Radziuk J; Van Vliet S
    Metabolism; 1979 Apr; 28(4):300-7. PubMed ID: 449682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum lipids, insulin, and glucagon after portacaval shunt in cirrhosis.
    Shurberg JL; Resnick RH; Koff RS; Ros E; Baum RA; Pallotta JA
    Gastroenterology; 1977 Feb; 72(2):301-4. PubMed ID: 830579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for an augmented glucagon dependence of hepatic glucose production in cirrhosis of the liver.
    Keller U; Sonnenberg GE; Burckhardt D; Perruchoud A
    J Clin Endocrinol Metab; 1982 May; 54(5):961-8. PubMed ID: 6120952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperglucagonemia in hepatic cirrhosis: its relation to hepatocellular dysfunction and normalization on recovery.
    Kabadi UM; Eisenstein AB; Tucci J; Pellicone J
    Am J Gastroenterol; 1984 Feb; 79(2):143-9. PubMed ID: 6364796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated growth hormone levels and insulin resistance in patients with cirrhosis of the liver.
    Shankar TP; Fredi JL; Himmelstein S; Solomon SS; Duckworth WC
    Am J Med Sci; 1986 Apr; 291(4):248-54. PubMed ID: 3518447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plasma level of glucagon in cirrhotic patients with portal hypertension during operation of portacaval shunts].
    Feng H; Zhang Z; Leng X; Li S; Zhu J; Du R
    Zhonghua Wai Ke Za Zhi; 1999 Apr; 37(4):222-4. PubMed ID: 11829825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin, C-peptide and glucagon levels during OGTT in hepatic cirrhosis and in patients with prehepatic block.
    Gerö L; Korányi L; Szalay F; Büki B; Tamás G
    Acta Diabetol Lat; 1982; 19(1):55-64. PubMed ID: 7041501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon and insulin metabolism in cirrhotic patients.
    Yoshida T; Ninomiya K; Matsumoto T; Baatar D; Bandoh T; Kitano S
    Hepatogastroenterology; 1998; 45(20):468-71. PubMed ID: 9638429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The implication of hyperglucagonemia and -insulinemia in liver cirrhotics].
    Yoshida T; Mitarai Y; Nagamine K; Kobayashi M
    Nihon Shokakibyo Gakkai Zasshi; 1989 Jun; 86(6):1273-80. PubMed ID: 2677448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma ammonia level in hepatic cirrhosis: role of glucagon.
    Kabadi UM; Eisenstein AB; Konda J
    Gastroenterology; 1985 Mar; 88(3):750-6. PubMed ID: 3881308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splanchnic and hepatic metabolism of somatostatin: a study in cirrhotic patients with a portacaval shunt.
    Webb S; Kravetz D; Bosch J; Wass JA; Evans J; Gomis R; Rees LH; Rodés J
    Hepatology; 1983; 3(2):193-7. PubMed ID: 6131859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure.
    Kuku SF; Jaspan JB; Emmanouel DS; Zeidler A; Katz AI; Rubenstein AH
    J Clin Invest; 1976 Sep; 58(3):742-50. PubMed ID: 956399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating somatostatin concentrations in healthy and cirrhotic subjects.
    Verrillo A; de Teresa A; Martino C; Pinto M; Golia R
    Metabolism; 1986 Feb; 35(2):130-5. PubMed ID: 2868381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distal splenorenal shunt and insulin secretion, plasma glucagon, and glucose homeostasis in cirrhosis.
    Trevisani F; Bernardi M; Giancane S; Arienti V; Mazziotti A; Cavallari A; Patrono D; Piazzi S; Gozzetti G; Gasbarrini G
    Nutrition; 1993; 9(2):133-9. PubMed ID: 8485325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic beta-cell function in cirrhotic patients with and without overt diabetes. C-peptide response to glucagon and to meal.
    Marchesini G; Melli A; Checchia GA; Mattioli L; Capelli M; Cassarani S; Zoli M; Pisi E
    Metabolism; 1985 Aug; 34(8):695-701. PubMed ID: 3894876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.